Providing a VOICE for Minnesota's MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 1992
Meetings & Education
Financial Advocacy & Patient Assistance
MSCO Educational Award
MSCO Advocacy Support
Patient Advocacy Organizations
State & Federal Resources
Find A Clinical Trial
Off-Label Use Literature
National Professional Organizations
MSCO Corporate Members
Become a Corporate Member
Industry News Archive
FDA Approves Ribociclib in Combination for Advanced, Metastatic Breast Cancer
On July 18, the Food and Drug Administration approved ribociclib (Kisqali, Novartis Pharmaceuticals Corp.) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.
The FDA also approved ribociclib in combination with fulvestrant for the treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.
Read the full FDA press release here.
Tweets by OSSatACCC